Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1192 participants.
Also called NCT07263308
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,192 participants
- Sponsor
- Registry
-
NCT07263308
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07263308. Randomized; no masking; primary purpose treatment. Start 2025-12-18 (actual); primary completion 2027-06-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
- Acronym
- ARISE-2
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Albumin
- Intervention (Procedure)
- Endovascular treatment
- Lead sponsor
- Capital Medical University
Record details
- Record id
cardio:ct-nct07263308- Content hash
d6a29c9ba2d5590f01e8d940a03e77f03399aa3c9871b7262a527011af3423d4